Bioinformatics is an interdisciplinary field of science that develops methods and software tools for understanding biological data, especially when the data sets are large and complex. Bioinformatics uses biology, chemistry, physics, computer science, computer programming, information engineering, mathematics and statistics to analyze and interpret biological data. The subsequent process of analyzing and interpreting data is referred to as computational biology.
The Medical Research Council (MRC) is responsible for co-coordinating and funding medical research in the United Kingdom. It is part of United Kingdom Research and Innovation (UKRI), which came into operation 1 April 2018, and brings together the UK's seven research councils, Innovate UK and Research England. UK Research and Innovation is answerable to, although politically independent from, the Department for Business, Energy and Industrial Strategy.
In biology and other experimental sciences, an in silico experiment is one performed on computer or via computer simulation. The phrase is pseudo-Latin for 'in silicon', referring to silicon in computer chips. It was coined in 1987 as an allusion to the Latin phrases in vivo, in vitro, and in situ, which are commonly used in biology. The latter phrases refer, respectively, to experiments done in living organisms, outside living organisms, and where they are found in nature.
Toxicogenomics is a subdiscipline of pharmacology that deals with the collection, interpretation, and storage of information about gene and protein activity within a particular cell or tissue of an organism in response to exposure to toxic substances. Toxicogenomics combines toxicology with genomics or other high-throughput molecular profiling technologies such as transcriptomics, proteomics and metabolomics. Toxicogenomics endeavors to elucidate the molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns that predict toxicity or the genetic susceptibility to it.
Chemogenomics, or chemical genomics, is the systematic screening of targeted chemical libraries of small molecules against individual drug target families with the ultimate goal of identification of novel drugs and drug targets. Typically some members of a target library have been well characterized where both the function has been determined and compounds that modulate the function of those targets have been identified. Other members of the target family may have unknown function with no known ligands and hence are classified as orphan receptors. By identifying screening hits that modulate the activity of the less well characterized members of the target family, the function of these novel targets can be elucidated. Furthermore, the hits for these targets can be used as a starting point for drug discovery. The completion of the human genome project has provided an abundance of potential targets for therapeutic intervention. Chemogenomics strives to study the intersection of all possible drugs on all of these potential targets.
The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. Two recent publications revisit the case for open science. Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current Chair is Anke Müller-Fahrnow (Germany), and previous Chairs have been Michael Morgan (U.K.), Wayne Hendrickson (U.S.A.), Markus Gruetter (Switzerland) and Tetsuyuki Maruyama (Japan). The founding and current CEO is Aled Edwards (Canada). The founding Members of the SGC Company were the Canadian Institutes of Health Research, Genome Canada, the Ontario Research Fund, GlaxoSmithKline and Wellcome Trust. The current Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda.
The Cambridge Biomedical Campus is the largest centre of medical research and health science in Europe. The site is located at the southern end of Hills Road in Cambridge, England.
David Haussler is an American bioinformatician known for his work leading the team that assembled the first human genome sequence in the race to complete the Human Genome Project and subsequently for comparative genome analysis that deepens understanding the molecular function and evolution of the genome.
Lawrence E. Hunter is a Professor and Director of the Center for Computational Pharmacology and of the Computational Bioscience Program at the University of Colorado School of Medicine and Professor of Computer Science at the University of Colorado Boulder. He is an internationally known scholar, focused on computational biology, knowledge-driven extraction of information from the primary biomedical literature, the semantic integration of knowledge resources in molecular biology, and the use of knowledge in the analysis of high-throughput data, as well as for his foundational work in computational biology, which led to the genesis of the major professional organization in the field and two international conferences.
ChEMBL or ChEMBLdb is a manually curated chemical database of bioactive molecules with drug inducing properties. It is maintained by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL), based at the Wellcome Trust Genome Campus, Hinxton, UK.
Cyrus Homi Chothia was an English biochemist who was an emeritus scientist at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) at the University of Cambridge and emeritus fellow of Wolfson College, Cambridge.
Aviv Regev is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member at the Broad Institute of MIT and Harvard and professor at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.
The Szent-Györgyi Prize for Progress in Cancer Research, established by National Foundation for Cancer Research (NFCR) and named in honor of Albert Szent-Györgyi, Nobel laureate and co-founder of NFCR, has been awarded annually since 2006 to outstanding researchers whose scientific achievements have expanded the understanding of cancer and whose vision has moved cancer research in new directions. The Szent-Györgyi Prize honors researchers whose discoveries have made possible new approaches to preventing, diagnosing and/or treating cancer. The Prize recipient is honored at a formal dinner and award ceremony and receives a $25,000 cash prize. In addition, the recipient leads the next "Szent-Györgyi Prize Committee" as honorary chairman.
Sarah Amalia Teichmann is a German scientist who is head of cellular genetics at the Wellcome Sanger Institute and a visiting research group leader at the European Bioinformatics Institute (EMBL-EBI). She serves as director of research in the Cavendish Laboratory, at the University of Cambridge and a senior research fellow at Churchill College, Cambridge.
Núria López Bigas is a Spanish biologist and research professor with expertise in medical genetics, computational biology, and bioinformatics. She is an ICREA professor at Pompeu Fabra University and she also leads the Biomedical Genomics Research Group at the Institute for Research in Biomedicine in Barcelona, Spain. Her research is focused on developing computational approaches to investigate cancer genomes.
Mark S. Boguski was an American pathologist specializing in computational analysis and structural biology, He was elected in 2001 to the U.S. National Academy of Medicine, and was a Fellow of the American College of Medical Informatics.
Christophe Dessimoz is a Swiss National Science Foundation (SNSF) Professor at the University of Lausanne, Associate Professor at University College London and a group leader at the Swiss Institute of Bioinformatics. He was awarded the Overton Prize in 2019 for his contributions to computational biology. Starting in April 2022, he will be joint executive director of the SIB Swiss Institute of Bioinformatics, along with Ron Appel.
Xiaole Shirley Liu (刘小乐) is computational biologist, cancer researcher, and entrepreneur. She has been a Professor in the Department of Data Sciences at the Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health. She is now the co-founder and CEO of GV20 Therapeutics.
Corey Nislow is an American geneticist and molecular biologist. He is a Professor of genomics, pharmaceutical science and biochemistry at the University of British Columbia.
Jasmin Fisher, is an Israeli-British biologist who is Professor of computational biology at University College London. She is Group Leader of the Fisher Lab at UCL Cancer Institute, which develops state-of-the-art computational models and analysis techniques to study cancer evolution and mechanisms of drug resistance to identify better personalised treatments for cancer patients.
